(Q33265964)

English

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

phase II clinical trial

0 references

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

pancreatic cancer

1 reference

based on heuristic

inferred from title

Marco Niedergethmann

5

object named as

Marco Niedergethmann

0 references

1

object named as

Helmut Friess

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

author name string

Jan M Langrehr

2

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Helmut Oettle

3

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Jochen Raedle

4

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Christian Dittrich

6

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Dieter K Hossfeld

7

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Herbert Stöger

8

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Bart Neyns

9

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Peter Herzog

10

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Pascal Piedbois

11

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Frank Dobrowolski

12

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Werner Scheithauer

13

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Robert Hawkins

14

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Frieder Katz

15

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Peter Balcke

16

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Jan Vermorken

17

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Simon van Belle

18

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Neville Davidson

19

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Albert Abad Esteve

20

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Daniel Castellano

21

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Jörg Kleeff

22

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Adrien A Tempia-Caliera

23

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Andreas Kovar

24

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Johannes Nippgen

25

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

language of work or name

0 references

publication date

11 December 2006

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

285

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

copyright license

Creative Commons Attribution 2.0 Generic

1 December 2006

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

https://scigraph.springernature.com/pub.10.1186/1471-2407-6-285

0 references

Cancer statistics, 2005

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

New perspectives in the management of pancreas cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Integrin activation controls metastasis in human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Role of integrins in angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Requirement of vascular integrin alpha v beta 3 for angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1764757

28 July 2018

alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-285

21 January 2018

Specific alpha v integrin receptors modulate K1735 murine melanoma cell behavior.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-285

21 January 2018

Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-285

21 January 2018

Combined modality radioimmunotherapy. Promise and peril

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-285

21 January 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-285

21 January 2018

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-285

21 January 2018

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-285

21 January 2018

Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-285

21 January 2018

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-285

21 January 2018

Estimates of cancer incidence and mortality in Europe in 1995

1 reference

https://pubmed.ncbi.nlm.nih.gov/17156477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/17156477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins

1 reference

https://pubmed.ncbi.nlm.nih.gov/17156477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17156477

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-6-285

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33265964&oldid=1802565735"